<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624570</url>
  </required_header>
  <id_info>
    <org_study_id>CPKC412AUS56X</org_study_id>
    <nct_id>NCT02624570</nct_id>
  </id_info>
  <brief_title>Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy</brief_title>
  <acronym>AMLFLT3</acronym>
  <official_title>An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide access to Midostaurin and gather additional safety
      data on the combination of Midostaurin and standard of care for adult patients with newly
      diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who
      are eligible for standard induction and consolidation chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to provide Midostaurin (study drug) treatment to newly diagnosed
      FLT3 mutated (ITD or TKD) AML adult patients (18 years or older) eligible for standard
      standard induction (cytarabine + daunorubicin/Idarubicin) and consolidation (cytarabine)
      chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Acute Myeloid Leukemia (AML) With</condition>
  <condition>FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midostaurin</intervention_name>
    <description>Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)</description>
    <other_name>PKC412</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Written informed consent must be obtained prior to any screening procedures. Patients must
        meet all Inclusion Criteria:

          -  Patient is able to communicate well with the investigator, to understand and comply
             with the requirements of the study.

          -  Patients must be 18 years of age or older; elderly patients must be fit to receive
             intensive induction and consolidation chemotherapy

          -  Patients must have a documented FLT3 mutation (ITD or TKD)

          -  Patients must have an ECOG Performance Status of ≤ 2

          -  Patients must have a documented unequivocal diagnosis of AML according to WHO 2008
             classification (&gt;20% blasts in the bone marrow and/or peripheral blood), excluding M3
             (acute promyelocytic leukemia).

          -  Patients requiring intrathecal chemotherapy must have a minimum washout of 48 hours
             prior to the first dose of midostaurin

          -  AML patients with a history of antecedent treatment for myelodysplasia (MDS), e.g.
             azacitidine or decitabine, remain eligible for treatment on this study. These agents
             must have been discontinued for a period of at least 30 days or 5 half-lives of the
             drug (whichever is greater) before midostaurin can be administered.

          -  Secondary AML, e.g. patients with antecedent history of treatment for prior malignancy
             Patients must have the following laboratory values (Direct Bilirubin ≤ 2.5 x ULN,
             Serum Creatinine ≤ 2.5 x ULN)

        Exclusion Criteria:

        Patients eligible for this study must not meet any of the following criteria:

          -  Prior therapy for AML with the following exceptions: (emergency leukapheresis,
             emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 5 days, cranial RT
             for CNS leukostasis (one dose only), growth factor/cytokine support)

          -  Patients with LVEF less than 45% (by echocardiogram or MUGA) or symptomatic congestive
             heart failure, Class III or IV according to New York Heart Association (NYHA)
             classification

          -  Patients with any uncontrolled illness, including, but not limited to, acute or
             chronic pancreatitis or uncontrolled infection

          -  QTc &gt;500 msec on screening ECG. History of hypersensitivity to any drugs or
             metabolites of similar chemical classes as the IMP.

          -  Participation in a prior investigational interventional (drug) study with
             administration of the investigational product within 30 days or 5 half-lives of the
             investigational product, whichever is longer.

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, including women whose career, lifestyle, or sexual orientation
             precludes intercourse with a male partner and women whose partners have been
             sterilized by vasectomy or other means, UNLESS they are using two birth control
             methods.

          -  Sexually active males should not father a child during this study and for upto 5
             months following.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>480-342-2545</phone>
    </contact>
    <investigator>
      <last_name>Lisa Sproat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Jordan Research and Education Center ABSMC Comprehensive Cancer Ctr</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>510-204-3428</phone>
    </contact>
    <investigator>
      <last_name>Oleg Krijanovski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center Department of Hematology &amp; HCT</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>+00 626 256 4673 x62405</phone>
    </contact>
    <investigator>
      <last_name>Al Malki Monzr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Judes Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Steven Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Family Comp Cancer Cntr</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>714-456-5153</phone>
    </contact>
    <investigator>
      <last_name>Deepa Jeyakumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest Kaiser</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>303-861-3302</phone>
    </contact>
    <investigator>
      <last_name>Susan M Freeman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital Poudre Valley Hospital -U of C</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Steven R. Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System Memorial Healthcare System</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>954-265-1846</phone>
    </contact>
    <investigator>
      <last_name>Yehuda Deutsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center at Orlando Health Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Julio Hajdenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute SC - 5</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>813-745-3685</phone>
    </contact>
    <investigator>
      <last_name>Kendra Sweet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Georgia Cancer Center Pharmacy</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>706-721-2171</phone>
    </contact>
    <investigator>
      <last_name>Locke J Bryan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center Dept.of Rush UniversityMedCtr.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>312-563-2540</phone>
    </contact>
    <investigator>
      <last_name>Melissa Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>773-702-4400</phone>
    </contact>
    <investigator>
      <last_name>Hongtao Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Institute Indiana Blood and Marrow Trans</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>+1 317 528 7298</phone>
    </contact>
    <investigator>
      <last_name>Michael John Dugan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ft. Wayne Medical Oncology &amp; Hematology, Inc.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>219-484-8830</phone>
    </contact>
    <investigator>
      <last_name>Sunil Babu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>+1 502-899-3366 X152</phone>
      <phone_ext>152</phone_ext>
    </contact>
    <investigator>
      <last_name>Don A. Stevens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville / James Graham Brown Cancer Center Louisville 529-539</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>502-562-3429</phone>
    </contact>
    <investigator>
      <last_name>Maxim Krim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>504-588-5135</phone>
    </contact>
    <investigator>
      <last_name>Hana Safah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oschner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>312-942-5495</phone>
    </contact>
    <investigator>
      <last_name>Andrew Dalovisio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>617-636-7438</phone>
    </contact>
    <investigator>
      <last_name>Kellie Sprague</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute Harper Hosp. Invest. Pharmacy</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jay Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital SC</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>313-916-1784</phone>
    </contact>
    <investigator>
      <last_name>Ahmad Mattour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>507-284-2358</phone>
    </contact>
    <investigator>
      <last_name>Mark R. Litzow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialist/Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>402-991-8070</phone>
    </contact>
    <investigator>
      <last_name>Gamini S Soori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Healthcare Partners Medical Group</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>702-735-7154</phone>
    </contact>
    <investigator>
      <last_name>Vikas Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College NY Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>212-746-6736</phone>
    </contact>
    <investigator>
      <last_name>Gail J Roboz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center Univ of Rochester (7)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>724-900-0558</phone>
    </contact>
    <investigator>
      <last_name>Jane L. Liesveld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest Kaiser Permanente Northwest</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>97015</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>+1 503 249 3316</phone>
    </contact>
    <investigator>
      <last_name>Abdul Hai Mansoor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State University / Milton S. Hershey Medical Center Penn State Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-085</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>717-531-8309</phone>
    </contact>
    <investigator>
      <last_name>David Claxton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104 4283</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>215-615-5858</phone>
    </contact>
    <investigator>
      <last_name>Alexander Perl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Hematology-Oncology Division</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>843-792-9300</phone>
    </contact>
    <investigator>
      <last_name>Robert K. Stuart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlanger Medical Center Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>+1 423 752 5004</phone>
    </contact>
    <investigator>
      <last_name>Robert Matthew Graham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center, Clinical Trials Center Division Hematology/Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>615-322-6515</phone>
    </contact>
    <investigator>
      <last_name>Stephen Strickland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch University of Texas MB</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1188</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>409-772-1164</phone>
    </contact>
    <investigator>
      <last_name>Avi B. Markowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGovern Medical School at the University of Texas Health</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>713-486-5660</phone>
    </contact>
    <investigator>
      <last_name>Modupe Idowu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>713-600-0992</phone>
    </contact>
    <investigator>
      <last_name>Julio Peguero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>+1 210 575 4238</phone>
    </contact>
    <investigator>
      <last_name>Jose Carlos Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare - Huntsman Cancer Clinics Intermountain Healthcare (2)</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>+1 801408 3729</phone>
    </contact>
    <investigator>
      <last_name>Julie Asch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute Univ. of Utah Hematology Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-0550</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>801-585-2626</phone>
    </contact>
    <investigator>
      <last_name>Tibor Kovacsovics</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates Virginia Oncology Assoc. (6)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>757-213-5624</phone>
    </contact>
    <investigator>
      <last_name>Scott J. Cross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>206-215-2658</phone>
    </contact>
    <investigator>
      <last_name>Raya Mawad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Puget Sound Health Care System VAMC Seattle, WA Divison</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thomas Chauncey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital and Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>509-663-8711</phone>
    </contact>
    <investigator>
      <last_name>Lindsay Overton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheyenne Regional Medical Center</name>
      <address>
        <city>Cheyenne</city>
        <state>Wyoming</state>
        <zip>82001</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>917-331-0613</phone>
    </contact>
    <investigator>
      <last_name>Natalie Alana Workman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>FLT3</keyword>
  <keyword>ITD</keyword>
  <keyword>TKD</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>induction</keyword>
  <keyword>consolidation</keyword>
  <keyword>continuation</keyword>
  <keyword>EAP</keyword>
  <keyword>ETP</keyword>
  <keyword>midostaurin</keyword>
  <keyword>PKC412</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midostaurin</mesh_term>
    <mesh_term>Staurosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

